Two of the largest-ever biotech initial public offerings (IPOs) are scheduled to go ahead in the coming week, after a flurry of smaller stock market launches last week.
Orchard Therapeutics has said it plans to file for approval for a gene therapy for the life-threatening rare disease metachromatic leukodystrophy (MLD) in Europe, after publishing new data.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
